Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress

Protagonist Therapeutics Inc ( (PTGX) ) has released its Q2 earnings. Here is a breakdown of the information Protagonist Therapeutics Inc presented to its investors.

Protagonist Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel peptide-based therapeutics, primarily targeting inflammatory and blood disorders. The company operates within the biotechnology sector and is known for its proprietary peptide technology platform.

Protagonist Therapeutics recently reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical development programs. The company has submitted a New Drug Application (NDA) for icotrokinra to the U.S. FDA for the treatment of plaque psoriasis and is preparing for an NDA submission for rusfertide in polycythemia vera by the end of the year.

Key financial metrics from the report include cash and marketable securities totaling $673 million, providing a cash runway through 2028. The company reported a net loss of $34.8 million for the quarter, with increased research and development expenses attributed to new product candidates. Revenue from license and collaboration agreements was $5.5 million, reflecting ongoing partnerships with Takeda and Johnson & Johnson.

Strategic developments include the presentation of Phase 3 trial data for rusfertide at the ASCO Annual Meeting and the advancement of early-stage assets PN-881 and PN-477. The company is also exploring a new anti-obesity peptide candidate, demonstrating its commitment to expanding its therapeutic pipeline.

Looking ahead, Protagonist Therapeutics remains focused on advancing its clinical programs and achieving regulatory milestones. The management is optimistic about the potential of its pipeline candidates to address unmet medical needs in inflammatory and blood disorders.